Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients—Is It Related to Immunosuppression Only?
by
, , , , and
Paulina Nazaruk
1, 
Marta Monticolo
1,
Anna Maria Jędrzejczak
1,
Natalia Krata
1,
Barbara Moszczuk
2,
Joanna Sańko-Resmer
3,
Tomasz Pilecki
1,
Arkadiusz Urbanowicz
1,
Michał Florczak
1,
Leszek Pączek
1,4,
Bartosz Foroncewicz
1,† and
Krzysztof Mucha
1,4,*,† 1
Department of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, Poland
2
Department of Clinical Immunology, Medical University of Warsaw, 02-006 Warsaw, Poland
3
Department of Nephrology Nursing, Medical University of Warsaw, 02-007 Warsaw, Poland
4
Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland
*
Author to whom correspondence should be addressed.
†
These authors contributed equally.
Vaccines 2021, 9(12), 1454; https://doi.org/10.3390/vaccines9121454
Submission received: 6 November 2021
/
Revised: 4 December 2021
/
Accepted: 6 December 2021
/
Published: 8 December 2021
(This article belongs to the Special Issue Assessment of Post-COVID-19 Complications and Vaccination Efficacy)
Abstract
:The BNT162b2 vaccine is reportedly effective in preventing severe disease in more than 90% of the general population, but its efficacy in transplant recipients remains controversial. We aimed to determine the immune response to the BNT162b2 vaccine in kidney (KTRs) and liver transplant recipients (LTRs). In this retrospective cohort study, we included randomly 65 KTRs and 65 LTRs, who received two 30 μg doses of BNT162b2 vaccine in 3-to6-week intervals. We analyzed the anti-SARS-CoV-2 spike protein IgG antibody (anti-S1 Ab) titer, biochemical liver and renal tests, immunosuppressive drug trough level, and clinical follow up 4–6 weeks after the first dose and 4–8 weeks after the second dose. The level of protective antibodies was 57.1% in KTRs and 88.9% in LTRs after the second dose. The anti-S1 Ab response was significantly associated with sex, age, and history of COVID-19. A tacrolimus dose at vaccination but not its trough level was significantly correlated with the increase in anti-S1 Ab titer after the second vaccine dose in LTRs. Rejection episodes did not occur after vaccination. Our results showed a higher than previously reported humoral response to the BNT162b2 vaccine in KTRs and LTRs, which was dependent upon age, type of transplanted organ, and immunosuppression.
Keywords:
BNT162b2 mRNA; COVID-19; kidney transplantation; liver transplantation; SARS-CoV-2; SOT; vaccination1. Introduction
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is the result of the complex interplay between viral dynamics and host immune responses [1]. Most end-organ complications that characterize severe COVID-19 are attributable to a dysregulated immune response that follows SARS-CoV-2 infection. In January 2021, two mRNA vaccines: mRNA-1273 and tozinameran (BNT162b2) were introduced to prevent COVID-19. Both vaccines are reportedly effective in preventing severe disease in more than 90% of the general population, across all age groups and in pre-specified subgroups at high risk of severe disease [2,3]. However, these trials excluded patients receiving chronic immunosuppressive therapy such as solid organ transplant (SOT) recipients.
There are several concerns about the use of SARS-CoV-2 vaccines in transplant recipients. First, theoretically, inducing alloimmunity might result in graft rejection. Vaccines could induce alloimmunity by stimulating previously alloreactive immune cells or through the non-specific stimulatory effects of adjuvants, which could lead to de novo alloimmunity. Indeed, such donor-specific antibodies (DSA) were previously detected in kidney transplant recipients (KTRs) and heart transplant recipients who received AS03-adjuvanted 2009 influenza A virus subtype H1N1 pandemic influenza vaccines [4,5,6]. Despite the potential reactogenicity risk, in clinical trials of both mRNA-1273 and BNT162b2 vaccines, there was no evidence of increased risk of rejection or autoimmune phenomena after the first dose [7,8]. Another concern related to mRNA vaccination is the virus-specific immune response and its duration. Pre-pandemic experience with licensed vaccines has shown that SOT recipients mount less robust immune responses to vaccines compared with non-transplant patients, regardless of the vaccine type [9]. The specific impact of each component of immunosuppression (IS) on vaccine immunogenicity is poorly understood.
The first study evaluating the immune response of 23 KTRs to the standard two-dose regimen of BNT162b2, revealed that only 22% were positive for anti-SARS-CoV-2 spike protein IgG antibody (anti-S1 Ab) after the second dose [10], whereas vaccination was effective in almost 100% of healthy controls. Additionally, the mean anti-S1 Ab titer of KTRs was significantly lower. In another study, 80 LTRs developed a substantially lower humoral response to the BNT162b2 vaccine than controls [11]. However, LTRs show superior results compared to other SOT recipients reported so far [12]. Factors related to serological Ab responses include age, renal function, and type of IS used [11]. Lastly, a case was reported of a lung transplant patient who failed to develop neutralizing Ab to SARS-CoV-2 after two doses of the BNT162b2 mRNA vaccine [13]. These data confirmed the theory/observation that SOT patients may have an impaired immune response following mRNA-based SARS-CoV-2 vaccination. Patients with a history of COVID-19 might benefit from a different approach. The rapid increase in SARS-CoV-2 neutralizing Ab after the first dose of BNT162b2 vaccine in a group of previously infected individuals was reported. They reached titers similar to those observed in naïve subjects only after the second dose [14]. These findings raise the question of whether a single vaccine injection might be sufficient for patients with COVID-19 history. Indications to booster with the third dose of the SARS-CoV-2 vaccine are currently under discussion [15,16,17]. Moreover, the coronavirus cross reactivity in the context of response to potential viral mutations was recently addressed [15]. These issues seem to be particularly important for all immunocompromised and chronic disease patients such as SOT recipients.
Considering the aforementioned concerns, we performed this study to assess the serum anti-S1 Ab levels as well as graft function in KTRs and LTRs after BNT162b2 vaccination.
2. Materials and Methods
2.1. Study Design
This was a retrospective cohort study of randomly chosen 65 KTRs and 65 LTRs, who -received two 30 µg doses of BNT162b2 vaccine at a dosing interval of 3-to-6 weeks. Patients were qualified by the designated staff at the Medical University of Warsaw—Infant Jesus Hospital vaccination center. The inclusion criteria were age over 18 years and stable graft function. Patients with a history of allergy to any vaccine, acute illness, or fever within 72 hours prior to vaccination, or any chronic medical condition considered progressive or uncontrolled and required hospitalization within the previous 3 months were disqualified from vaccination. A history of COVID-19 disease more than 2 months prior did not disqualify patients from vaccination.
As part of the standard follow up of patients after vaccination, anti-S1 Ab levels were measured during routine visits to the Transplant Outpatient Clinic: 4–6 weeks after the first dose and 4–8 weeks after the second dose. The clinical status of the patients and the biochemical parameters of the graft function were also assessed during these follow-up visits.
We did not include healthy controls as the response rate to vaccination in the general population was previously reported. Common patterns of Ab response to four different SARS-CoV-2 antigens after vaccination of healthy individuals is known [18]. Additionally, measuring the post-vaccination titers of COVID-19, is not recommended [19]. Therefore, taking into account the existing data from healthy subjects, the lack of recommendations to control their antibody titer, and retrospective study design, we did not include the control group. Medical records were reviewed, retrospectively, for: (1) the immune response to the vaccination as measured by anti-S1 Ab titers at two time points: 4–6 weeks after the first dose and 4–8 weeks after the second dose; and (2) the function of the transplanted kidney or liver following both BNT162b2 doses, defined by kidney and liver blood biochemical tests, immunosuppressive drug trough concentration, blood cell count, and clinical follow up. The difference between anti-S1 Ab titer after the first and second dose of vaccination was presented as delta (Δ) anti-S1 Ab.
2.2. Biochemical and Clinical Tests
Routine biochemical tests including blood morphology, serum creatinine, alanine aminotransferase (ALT); aspartate aminotransferase (AST); gamma-glutamyltranspeptidase (GGTP), alkaline phosphatase (ALP), bilirubin, complement proteins, urine analysis and urinary protein excretion were carried out using automatic biochemical analyzers: Cobas Integra 400 plus (Roche Diagnostics, Mannheim, Germany) and Elecsys 2010 Roche. Tacrolimus and cyclosporine trough concentrations were assessed with use of Architect Analyzer i2000SR (Abbott, Chicago, IL, USA).
The glomerular filtration rate (eGFR) was estimated according to the chronic kidney disease-epidemiology collaboration (CKD-EPI) equation. Body weight in kilograms was divided by the square of height in meters (kg/m2) to evaluate body mass index (BMI).
2.3. Anti-S1 Ab Testing
The SARS-CoV-2 IgG II Quant test (Abbott Laboratories, Chicago, IL, USA) was used to determine anti-S1 Ab level by designated personnel in the hospital laboratory. This is an immunochemical test using a microparticle and chemiluminescent marker (Chemiluminescent Microparticle Immunoassay, CMIA). It is used for both qualitative and quantitative IgG Ab determination, including neutralizing antibodies against the receptor-binding domain of the S1 subunit of the SARS-CoV-2 virus spike protein in human serum and plasma on the ARCHITECT analyzer. The units used in the test are arbitrary units per mL (AU/mL). The analytical measuring interval ranged from 21.0 AU/mL to 40.000 AU/mL, the cut-off was 50.0 AU/mL, and results <50.0 AU/mL were considered negative and >50 AU/mL were positive. The relationship between Abbott AU/mL and binding Ab units per mL (BAU/mL), which is a standardized unit according to the World Health Organization [20,21], is presented by the following formula [22]:
BAU/mL = 0.142 × AU/mL
However, 14 of 130 patients were tested for anti-S1 Ab in the laboratories of their place of residence. Their results were obtained using other types of tests and presented in different units (AU/mL, BAU/mL, international units per mL (IU/mL), relative units per mL (RU/mL)). It was not possible to establish a reliable mathematical correlation between the measurements of anti-S1 Ab concentrations obtained in different units; thus, they were excluded from the statistical analyses. However, they were included in the summary of the vaccine anti-S1 Ab protective level, according to each testing method cut-off. Therefore, 116 SOT recipients were selected for the final analyses.
2.4. Anti-Nucleocapsid Protein Ab Testing
To assess the potential effect of COVID-19 history on anti-S1 Ab level, anti-SARS-CoV-2 nucleocapsid protein IgG antibodies (anti-N Ab) were measured using CMIA technology and estimated as a relative light unit (RLU) by the Abbott test on the Alinity i analyzer (Abbot Laboratories). Results are expressed as an index (signal/cut-off [S/CO]). The index cut-off point was 1.40 (S/CO), therefore the results <1.40 (S/CO) were considered negative and >1.40 (S/CO) were positive. This measurement was performed twice: 4–6 weeks after the first vaccine dose, and 4–8 weeks after the second dose along with the anti-S1 Ab (Appendix A, Table A4).
Statistical analyses were performed in R version 3.6.1. and Statistica 13.1 (StatSoft). Results are expressed as the mean ± standard deviation (SD), median (MD) ± interquartile range (IQR), or a percentage value. All variables were tested for normal distribution by the Shapiro–Wilk test. Non-normally distributed variables were analyzed by non-parametric tests (Mann–Whitney U test and Kruskal–Wallis test). The association between parameters was analyzed using Spearman’s correlation. p < 0.05 was considered significant.
This study was approved by the Medical University of Warsaw Institutional Review Board (AKBE/182/2021).
3. Results
Between January and June 2021, 130 SOT recipients (65 KTRs and 65 LTRs) received 2 doses of BNT162b2 vaccine and underwent subsequent serologic testing for anti-S1 Ab. Positive response to vaccination was found in 58.5% of KTRs and 83.6% of LTRs. After exclusion of 14 individuals, who were tested in external laboratories with the use of incomparable methods, 116 patients (61 KTRs and 55 LTRs) were subject to further analyses. The mean age of KTRs and LTRs at vaccination was 54.4 years and 58.4 years, respectively; 54.1% of KTRs and 32.3% of LTRs were females. Depending on the transplanted organ type as well as the primary liver disease of the LTRs, they received mono-, double- or triple-drug maintenance IS consisting of: glicocorticosteroids (GS), azathioprine (AZA), mycophenolate mofetil (MMF), cyclosporine (CsA), tacrolimus (TAC), everolimus (EVR), or sirolimus (SIR).
A history of COVID-19 confirmed by a positive SARS-CoV-2 PCR test was documented in 8.2% of KTRs and 9.1% of LTRs. Interestingly, none of the KTRs in contrast to 60% of LTRs developed loss of smell or taste as a symptom of COVID-19. Detailed patients’ characteristics are summarized in Table 1.
Immune Response in SOT Patients
The anti-S1 Ab titer results of 116 patients were obtained after the first and/or the second dose of vaccine (Figure 1). Early response to BNT162b2 (after the first dose) was observed in 44.2% of KTRs and 63% of LTRs. The response rate evaluated after the second dose was 57.1% in 49 KTRs and 88.9% in 45 LTRs.
LTRs produced a significantly higher anti-S1 Ab titer after the second dose of vaccine than KTRs (Figure 2A,B; Table 2); however, the difference between the Δ anti-S1 Ab in LTRs and KTRs was non-significant (Figure 3A,B).
The influence of the autoimmune comorbidities could be evaluated only in LTRs, since the data on primary kidney diseases in the majority of KTRs is unknown. Interestingly, we found that the coexisting autoimmune diseases in LTRs had no influence on the response to vaccination compared to those LTRs with non-autoimmune etiology (Figure 4). We did not find such observations in the literature.
A significant association was observed between the Δ anti-S1 Ab and patient age and estimated glomerular filtration rate (eGFR). This relationship with age was significant in KTRs only. The anti-S1 Ab titer after the first and second vaccine doses was also correlated with age, particularly in KTRs. A positive anti-N Ab test was significantly correlated with anti-S1 Ab titers after the first and second doses of vaccine. Interestingly, such correlation after the 1st dose was significant in KTRs and LTRs, whereas after the 2nd dose was significant in KTRs only. In addition, the TAC dose at vaccination was significantly correlated with anti-S1 Ab titer after the second vaccine dose in LTRs. Such a correlation was not observed in patients taking CsA. There were no associations between serum trough concentrations of TAC or CsA and Δ anti-S1 Ab titer (Table 3). We found that female LTRs had a significantly higher response to vaccination than female KTRs, both after the first and the second dose (Table 4). The quantity of anti-S1 Abs is summarized in Table 2.
Spearman’s correlation analysis of age confirmed its significant association with the Δ anti-S1 Ab in KTRs (p = 0.004) (Figure 5A), but not in LTRs (p = 0.31) (Figure 5B). Additionally, we observed the relationship between sex and anti-S1 Ab levels. After the first dose, male KTRs produced a significantly higher amount of anti-S1 Ab than female KTRs. Furthermore, female LTRs had a better response to vaccination than female KTRs (Figure 5C,D and Table 4).
We found no correlation between number of immunosuppressive drugs taken (single-, double-, or triple-drug maintenance therapy) (Appendix A, Table A1) or blood type (Appendix A, Table A2 and Table A3) with the titer of anti-S1 Ab after the second dose of vaccine in KTRs and LTRs. In KTRs who received triple-drug maintenance IS, a significant association between gender and anti-S1 Ab titer was observed (Appendix A, Table A2). In KTRs on double-drug therapy, the time from transplantation was positively correlated with anti-S1 Ab response to vaccination (Appendix A, Table A3). In LTRs on monotherapy, the Δanti-S1 Ab was correlated with blood type (Appendix A, Table A2).
4. Discussion
The fundamental finding of our study was the unexpected high response rate to BNT162b2 vaccination in SOT recipients, and especially in LTRs. These results are up to date with the current worldwide discussion regarding the need for the third dose of vaccine. The response rate of an immunocompetent patient to the first dose of BNT162b2 vaccine varies between 74% and 91%, depending on the patient’s age; whereas, the second dose increases the rate of the seropositivity up to >90%, regardless of age [22]. In contrast, non-immunocompetent patients, including SOT recipients, have a much weaker humoral immune response defined by the anti-S Ab level. Of course, it depends on the type of transplanted organ and/or IS used. Studies have shown a response rate up to 37.5% of KTRs and 47.5% of LTRs following vaccination with BNT162b2 [11,23]. The success rate can be even lower, as reported by Boyarsky et al. [24], who found only 17% of patients with a positive anti-S1 Ab response after one dose of vaccine. Given such data, the average 74% positive response rate in our cumulative KTR and LTR groups was unexpected. It should be underlined that all of our patients were vaccinated at the same center, in a similar time frame, with the BNT162b2 mRNA vaccine ordered at the same time and patients were followed up homogenously by the same team of physicians. In our opinion, these factors should be considered in the discussion about the success rate of the vaccination. Both the percentage and difference between the humoral response to vaccination in our KTR (58.5%) and LTR (89.1%) groups need additional evaluation.
It is clear that the above differences may result from the IS used and type of transplanted organ [25]. Previous studies have shown the role of the impaired immune response to any vaccination in SOT patients, most likely because of the IS therapy [9]. The suppression of humoral immunity (e.g., by rituximab or methotrexate) in non-SOT patients can reduce the production of neutralizing Ab in response to other vaccines [26]. It is worth noting that the liver is an immunologically privileged organ, and a better response to vaccination by LTRs may be a result of this physiologic phenomenon. LTRs usually require less IS than KTRs and are more likely to be on a one- or two-drug maintenance therapy. Interestingly, our results did not reveal significant differences between the effect of two- or three-drug IS on the response to vaccination. The time from transplantation to vaccination also did not influence the response; however, TAC dose at vaccination correlated with anti-S1 Ab serum concentration after both doses. These observations suggest that IS intensity at the moment of vaccination (related to the type of transplanted organ), rather than its serum concentration may impact the response to vaccination.
The future knowledge about the impact of genetic background on humoral responses will help understanding interpersonal differences and could enable personalized approach to vaccinations. As LTRs usually require less IS than KTRs and repeatedly show superior response to vaccination compared to other SOT recipients, including KTRs [12], the intensity of IS may be a contributing factor. Furthermore, the IS protocol for LTRs used in our center allows its minimization in individuals with no autoimmune primary liver disease. This could influence the response to the vaccination; however, the number of patients in our study was insufficient to prove such influence. Therefore, larger population studies are necessary to answer this question. We found that anti-S1 Ab titers were associated with patients’ age, which is in line with the results of a recent study performed in the healthy population. Authors shown that BNT162b2 vaccine was effective in producing anti-SARS-CoV-2 IgG levels, and that humoral response was age- and gender-dependent [27]. However, in our case, only female LTRs responded better comparing to KTRs. We do not fully understand this phenomenon that definitely needs to be explained in a separate study.
The unexpected finding was the average anti-S1 Ab titer >40.000 AU/mL after the second dose in the LTR group with autoimmune primary liver diseases (primary sclerosing cholangitis or autoimmune hepatitis), which confirmed previous observations that autoimmunity itself does not hamper vaccination responses [28]. It is unclear whether the Abs are the crucial and only indicator of immunity or whether their absence leads to a complete lack of response to vaccination. Furthermore, people who have received a full course of vaccination due to cross-neutralization of at least some of the circulating SARS-CoV-2 variants have a positive response to the new SARS-CoV-2 variants [29]. The question is raised of whether recipients who have received vaccination, despite the lack of Ab production, may also have such a response to the new SARS- CoV-2 variants.
A very important issue emerged from the publication of the Krause et al. [30], who discussed the need of the third dose by the general population. Their viewpoint is that two doses seem to be sufficient and there are known risks of side effects. Therefore, boosting should be considered only if there is a clear evidence that it is appropriate. Previous studies have indicated that patients vaccinated with a third dose of SARS-CoV-2 vaccine presented with stronger immunity, were less likely to get infected, and had milder symptoms of SARS-CoV-2 infection [31,32]. The viewpoint of Krause and colleagues [30] are particularly important for non-immunocompetent patients. Among them, SOT patients experience many adverse effects due to the polytherapy, and their response to the vaccination is less predictable. Therefore, it seems all the more reasonable to refrain from administering a third dose of the vaccine to this patient population, particularly in the context of a possible high response rate to the first and second doses, as presented in our study.
It is possible that SOT patients need an individualized vaccination algorithm. This may include more than two doses in selected patients with a lower response to the first and second doses [10], or even a combined scheme with mRNA vaccines, protein/subunit vaccines, and vector-based vaccines [33,34]. We believe that patients who have produced no anti-S1 Ab after the second dose of vaccine should be candidates for additional immune testing in order to choose an optimal vaccination scheme.
Lastly, the socioeconomic status and geographic factors differentiating Poland from other European countries were recently discussed in relation to nearly ten times lower SARS-CoV-2 seroprevalence after the first wave of COVID-19 pandemic [35]. We think that genetic predispositions together with IS intensity and geographic factors could partially explain different from previously reported response to vaccination in our population.
SARS-CoV-2 vaccinations commenced in January 2021; therefore, we currently have a maximum of 6-month vaccine efficacy data available [36]. The BNT162b2 vaccine has a favorable safety profile and is highly efficacious in preventing COVID-19 in the short term. However, we do not know the long-term effects of vaccination, especially in non-immunocompetent patients including SOT recipients. Thus, follow-up of patients is needed for the next several years.
The current studies on post-vaccination response should provide a background to understand the immunology and biology of the COVID-19. Such results already have an impact on both, prevention and treatment strategies. The investigations to determine and verify the specific subtype of integrins to interact with the S SARS-CoV-2 protein are an example. The RGD-related peptides are currently being used in clinical trials, since blocking these interactions of the RGD motif may serve as a potential drug candidate for COVID-19 [37,38].
5. Conclusions
In conclusion, we showed a higher than previously reported humoral response to two vaccine doses, especially in LTRs, confirming that the majority of SOT recipients can achieve a sufficient level of serum anti-S1 Ab. The response to vaccination depends on many factors of which the patient’s age, type of transplanted organ, and IS used seem to be most important. We also confirmed the safety of BNT162b2 vaccination in KTRs and LTRs. Additional clinical observations and basic research are needed to define the background of the variable vaccine response in immunocompromised patients, including transplant recipients.
Author Contributions
Research conceptualization, P.N., B.F. and K.M.; data curation, P.N., M.M., A.M.J., B.M., J.S.-R., T.P., A.U., M.F. and K.M.; formal analysis P.N., N.K., B.F. and K.M.; methodology N.K., B.F. and K.M.; project administration P.N. and K.M.; supervision B.F. and K.M.; visualization P.N., M.M., A.M.J., N.K. and K.M.; writing—original draft P.N., M.M., A.M.J., N.K., B.M., B.F. and K.M.; writing—review and editing P.N., L.P., B.F. and K.M. All authors have read and agreed to the published version of the manuscript.
Funding
No funding was received for this work.
Institutional Review Board Statement
This study was approved by the Medical University of Warsaw Institutional Review Board (AKBE/182/2021).
Informed Consent Statement
As this study is a retrospective cohort study, no informed consent was needed from the subjects involved in the study.
Data Availability Statement
Data available on request due to privacy restrictions, the data presented in this study are available on request from the corresponding author.
Acknowledgments
We thank Magdalena Zielenkiewicz, from the Institute of Mathematics in the Faculty of Mathematics, Informatics and Mechanics at University of Warsaw for her help with the statistical analyses. The routine laboratory tests were performed at the diagnostic laboratory of Infant Jesus Hospital, University of Warsaw, during routine patient visit to the Nephrology and Transplantation Outpatient Clinic.
Conflicts of Interest
The authors have no conflict of interest to declare, and no funding was received for this work.
Appendix A
Table A1.
Correlation of SARS-CoV-2 spike protein Ab concentration (AU/mL) after BNT162b2 vaccination to maintenance immunosuppression in KTRs and LTRs.
Table A1.
Correlation of SARS-CoV-2 spike protein Ab concentration (AU/mL) after BNT162b2 vaccination to maintenance immunosuppression in KTRs and LTRs.
| Mono-Therapy | Double-Therapy | Triple-Therapy | p-Value | ||||
|---|---|---|---|---|---|---|---|
| n | MD (IQR) | n | MD (IQR) | n | MD (IQR) | ||
| KTRs | |||||||
| Δ anti-S1 Ab ‡ | n.a. | n.a. | 10 | 55.4 (1619.3) | 30 | 1722.3 (5014.6) | 0.54 * |
| Ab after 2nd dose | n.a. | n.a. | 11 | 99.5 (19,056.5) | 38 | 1434.3 (8823.5) | 0.52 * |
| Ab after 1st dose | n.a. | n.a. | 15 | 49.6 (3753.2) | 37 | 36.0 (5344.7) | 0.79 * |
| LTRs | |||||||
| Δ anti-S1 Ab ‡ | 17 | 1006.7 (4380.2) | 10 | 274.7 (3611.4) | 10 | 1412.5 (7708.6) | 0.76 † |
| Ab after 2nd dose | 20 | 4132.8 (12,768.8) | 14 | 4967.0 (21,904.5) | 12 | 6155.2 (21,904.5) | 0.98 † |
| Ab after 1st dose | 21 | 314.7 (3538.2) | 14 | 15.7 (10,404.8) | 11 | 263.0 (6192.0) | 0.68 † |
n—number of observations; values are set as median (MD) and interquartile range (IQR); * Mann–Whitney test; p-value < 0.05 was considered significant (comparison of variables in a group double-therapy and triple-therapy); † Kruskal–Wallis test; (p-value < 0.05 was considered significant (comparison of variables in a group mono-therapy, double-therapy and triple-therapy); ‡ difference between anti-SARS-CoV-2 spike protein antibody titer after the first and the second dose of BNT162b2 vaccine; 1st dose = 4–6 weeks after the first dose of vaccination; 2nd dose = 4–8 weeks after the second dose of vaccination; Ab = SARS-CoV-2 spike protein antibody; BNT162b2 = BioNTech/Pfizer COVID-19 mRNA vaccine; KTRs = kidney transplant recipients; LTRs = liver transplant recipients; n.a. = not available.
Table A2.
Associations of SARS-CoV-2 spike 1 protein Ab concentration (AU/mL) after BNT162b2 vaccination with demographic and clinical variables in KTRs and LTRs depending on the maintenance immunosuppression.
Table A2.
Associations of SARS-CoV-2 spike 1 protein Ab concentration (AU/mL) after BNT162b2 vaccination with demographic and clinical variables in KTRs and LTRs depending on the maintenance immunosuppression.
| Parameter | Sex | Blood Type | Autoimmune vs. Non-Autoimmune Cause of Liver Transplantation | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | KTRs | LTRs | KTRs | LTRs | LTRs | ||||||||||||||
| Mono-therapy | |||||||||||||||||||
| Variable | M (n = 0) | F (n = 0) | p-value * | M (n = 10) | F (n = 14) | p-value * | A (n = 0) | B (n = 0) | AB (n = 0) | O (n = 0) | p-value † | A (n = 4) | B (n = 8) | AB (n = 0) | O (n = 11) | p-value † | Yes (n = 3) | No (n = 21) | p-value * |
| Δ anti-S1 Ab ‡ | n.a. | n.a. | n.a. | 2370.4 (3826.6) | 590.7 (4684.3) | 0.65 | n.a. | n.a. | n.a. | n.a. | n.a. | 2384.4 (9504.6) | 232 (351.4) | n.a. | 4173.1 (4180.3) | 0.031 | 1236.7 (27,619.1) | 684.35 (4612.2) | 0.34 |
| Ab after 2nd dose | n.a. | n.a. | n.a. | 1593.3 (3372.5) | 7116.2 (28,621.3) | 0.132 | n.a. | n.a. | n.a. | n.a. | n.a. | 6726.9 (21,715.9) | 1210.2 (32,756.8) | n.a. | 3887.1 (4328.1) | 0.53 | 2500 (31,223.5) | 4378.4 (8028.6) | 1 |
| Ab after 1st dose | n.a. | n.a. | n.a. | 137.8 (275.8) | 1034.9 (7418) | 0.180 | n.a. | n.a. | n.a. | n.a. | n.a. | 307.9 (17,748) | 94.3 (7566) | n.a. | 349.8 (3456.4) | 0.59 | 1263 (3604.4) | 257.55 (7499.8) | 1 |
| Double-therapy | |||||||||||||||||||
| Variable | M (n = 6) | F (n = 10) | p-value * | M (n = 4) | F (n = 14) | p-value * | A (n = 4) | B (n = 4) | AB (n = 1) | O (n = 6) | p-value † | A (n = 7) | B (n = 3) | AB (n = 2) | O (n = 5) | p-value † | Yes (n = 8) | No (n = 9) | p-value * |
| Δ anti-S1 Ab ‡ | 1619.3 (17,595.2) | 11.3 (99.5) | 0.30 | 2662.5 (5030.4) | 271.6 (2240.4) | 0.51 | 52.2 (856.9) | 8791.5 (17,617.4) | n.a. | 11.3 (49,526.5) | 0.96 | 869.4 (3231.6) | n.a. | n.a. | 84.8 (125) | 0.088 | 144.15 (193.1) | 2251.6 (5177.7) | 0.46 |
| Ab after 2nd dose | 4969.1 (19,037.8) | 99.5 (846.3) | 0.65 | 1013 (8766.7) | 14160.4 (24,085.9) | 0.53 | 52.3 (4986.1) | 9551.3 (19,037.8) | n.a. | 10560.6 (30,493.3) | 0.61 | 9555.3 (21,904.5) | 8920.9 (33,722.2) | n.a. | 154.2 (414.9) | 0.118 | 402.1 (22,165.6) | 14,160.4 (23,475) | 0.096 |
| Ab after 1st dose | 1470 (8208.8) | 2.7 (1632.3) | 0.24 | 6.9 (3743.2) | 24.5 (14,939.5) | 0.69 | 0.015 (4129.2) | 62.8 (748.2) | n.a. | 2692.8 (9409.9) | 0.21 | 2832.2 (10,404.8) | n.a. | n.a. | 0 (3.5) | 0.088 | 0 (6.9) | 4691.6 (17,884.7) | 0.153 |
| Triple-therapy | |||||||||||||||||||
| Variable | M (n = 22) | F (n = 23) | p-value * | M (n = 1) | F (n = 12) | p-value * | A (n = 15) | B (n = 5) | AB (n = 8) | O (n = 16) | p-value † | A (n = 5) | B (n = 3) | AB (n = 0) | O (n = 5) | p-value † | Yes (n = 10) | No (n = 3) | p-value * |
| Δ anti-S1 Ab ‡ | 3704.2 (8330.1) | 5.5 (2974.3) | 0.094 | n.a. | 1767.3 (7708.6) | n.a. | 347.9 (4256) | 1333.3 (2974.3) | 4009.6 (7024.2) | 0 (5014.6) | 0.64 | 3854.3 (12,117.7) | n.a. | n.a. | 1412.5 (1900.5) | 0.91 | 1767.3 (7708.6) | 385.5 (10,234.5) | 0.91 |
| Ab after 2nd dose | 4587.3 (28,130.5) | 3.7 (3016.5) | 0.012 | n.a. | 7959.3 (15130) | n.a. | 347.9 (13,235.4) | 1.1 (1357.1) | 4454.2 (10,470.6) | 779.9 (8823.5) | 0.20 | 10497.5 (25,602.7) | 296.8 (15,426.8) | n.a. | 2728.3 (5409.6) | 0.29 | 7959.3 (14,321.2) | 385.5 (10,497.5) | 0.36 |
| Ab after 1st dose | 93.4 (17,725.7) | 1.8 (1488.6) | 0.098 | n.a. | 329.8 (6144) | n.a. | 4 (8979.4) | 23.8 (42.2) | 2209.8 (17,725.7) | 33.3 (1045.7) | 0.77 | 20198.3 (39,670.3) | n.a. | n.a. | 48 (874.2) | 0.139 | 635.4 (23,036.8) | 0 (263) | 0.122 |
n—number of patients in selected subgroups; values are set as the median (MD) and interquartile range (IQR); * Mann–Whitney test. p < 0.05 was considered statistically significant; † Kruskal–Wallis test; p < 0.05 was considered statistically significant; ‡ difference between anti-SARS-CoV-2 spike protein antibody titer after the first and second doses of BNT162b2 vaccine; 1st dose = 4–6 weeks after the first dose of vaccination; 2nd dose = 4–8 weeks after the second dose of vaccination; Ab = Sars-anti-SARS-CoV-2 spike protein antibody; BNT162b2 = BioNTech/Pfizer COVID-19 mRNA vaccine; F = female; KTRs = kidney transplant recipients; LTRs = liver transplant recipients; M = male; n.a. = not available.
Table A3.
Associations of SARS-CoV-2 spike protein Ab concentration (AU/mL) after BNT162b2 vaccination with BMI and time from transplantation in KTRs and LTRs depending on the number of immunosuppressive drugs.
Table A3.
Associations of SARS-CoV-2 spike protein Ab concentration (AU/mL) after BNT162b2 vaccination with BMI and time from transplantation in KTRs and LTRs depending on the number of immunosuppressive drugs.
| Parameter | BMI | Time from Transplantation | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | KTRs | LTRs | KTRs | LTRs | ||||||||
| Variable | n | p-Value * | R | n | p-Value * | R | n | p-Value * | R | n | p-Value * | R |
| Mono-therapy | ||||||||||||
| Δ anti-S1 Ab † | n.a. | n.a. | n.a. | 17 | 0.48 | −0.184 | n.a. | n.a. | n.a. | 17 | 0.40 | 0.217 |
| Ab after 2nd dose | n.a. | n.a. | n.a. | 20 | 0.64 | −0.111 | n.a. | n.a. | n.a. | 20 | 0.37 | 0.213 |
| Ab after 1st dose | n.a. | n.a. | n.a. | 20 | 0.46 | −0.176 | n.a. | n.a. | n.a. | 21 | 0.50 | 0.154 |
| Double-therapy | ||||||||||||
| Δ anti-S1 Ab † | 10 | 0.73 | −0.127 | 10 | 0.83 | −0.079 | 10 | 0.37 | 0.321 | 10 | 0.75 | −0.117 |
| Ab after 2nd dose | 11 | 0.50 | −0.227 | 14 | 0.081 | 0.481 | 11 | 0.049 | 0.603 | 14 | 0.163 | −0.394 |
| Ab after 1st dose | 14 | 0.60 | −0.153 | 13 | 0.62 | 0.153 | 13 | 0.019 | 0.639 | 13 | 0.54 | −0.188 |
| Triple-therapy | ||||||||||||
| Δ anti-S1 Ab † | 30 | 0.48 | −0.134 | 10 | 0.062 | −0.608 | 30 | 0.84 | −0.038 | 10 | 0.51 | −0.238 |
| Ab after 2nd dose | 38 | 0.70 | 0.064 | 12 | 0.059 | −0.559 | 38 | 0.77 | 0.049 | 12 | 0.173 | −0.421 |
| Ab after 1st dose | 36 | 0.46 | 0.126 | 11 | 0.43 | −0.267 | 36 | 0.66 | 0.076 | 11 | 0.84 | 0.067 |
n—number of observations for selected pairs of parameters; * Spearman’s test p < 0.05 was considered statistically significant (comparison of variables in a group all participants, KTRs and LTRs); † difference between anti-SARS-CoV-2 spike protein antibody titer after the first and second doses of BNT162b2 vaccine; 1st dose = 4–6 weeks after the first dose of vaccination; 2nd dose = 4–8 weeks after the second dose of vaccination; Ab = SARS-CoV 2 spike 1 protein antibody; BMI = body mass index; BNT162b2 = BioNTech/Pfizer COVID-19 mRNA vaccine; KTRs = kidney transplant recipients; LTRs = liver transplant recipients; n.a. = not available.
Table A4.
The results of anti-SARS-CoV-2 nucleocapsid protein Ab assays in all patients regardless of con-firmed COVID-19.
Table A4.
The results of anti-SARS-CoV-2 nucleocapsid protein Ab assays in all patients regardless of con-firmed COVID-19.
| KTRs | LTRs | p-Value * | |||
|---|---|---|---|---|---|
| Anti-N Ab S/CO | n | MD (IQR) | n | MD (IQR) | |
| After 1st dose | 53 | 0.06 (0.26) | 45 | 0.05 (0.77) | 0.946 |
| After 2nd dose | 25 | 0.0 (0.0) | 21 | 0.0 (0.31) | 0.067 |
n—number of observations; values are set as the median (MD) and interquartile range (IQR); * Mann–Whitney U Test, p < 0.05 was considered statistically significant; 1st dose = 4–6 weeks after the first dose; 2nd dose = 4–8 weeks after the second dose; Anti-N Ab = anti-SARS-CoV-2 nucleocapsid protein antibody; BNT162b2 = BioNTech/Pfizer COVID-19 mRNA vaccine; KTRs = kidney transplant recipients; LTRs = liver transplant recipients; S/CO—signal/cut off.
References
- Tay, M.Z.; Poh, C.M.; Rénia, L.; MacAry, P.A.; Ng, L.F.P. The trinity of COVID-19: Immunity, inflammation and intervention. Nat. Rev. Immunol. 2020, 20, 363–374. [Google Scholar] [CrossRef]
- Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef] [PubMed]
- Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021, 384, 403–416. [Google Scholar] [CrossRef]
- Katerinis, I.; Hadaya, K.; Duquesnoy, R.; Ferrari-Lacraz, S.; Meier, S.; van Delden, C.; Martin, P.Y.; Siegrist, C.A.; Villard, J. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am. J. Transplant. 2011, 11, 1727–1733. [Google Scholar] [CrossRef]
- Schaffer, S.A.; Husain, S.; Delgado, D.H.; Kavanaugh, L.; Ross, H.J. Impact of adjuvanted H1N1 vaccine on cell-mediated rejection in heart transplant recipients. Am. J. Transplant. 2011, 11, 2751–2754. [Google Scholar] [CrossRef]
- Fairhead, T.; Hendren, E.; Tinckam, K.; Rose, C.; Sherlock, C.H.; Shi, L.; Crowcroft, N.S.; Gubbay, J.B.; Landsberg, D.; Knoll, G.; et al. Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients. Transpl. Infect. Dis. 2012, 14, 575–583. [Google Scholar] [CrossRef]
- Boyarsky, B.J.; Ou, M.T.; Greenberg, R.S.; Teles, A.T.; Werbel, W.A.; Avery, R.K.; Massie, A.B.; Segev, D.L.; Garonzik-Wang, J.M. Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplantation 2021, 105, e56–e57. [Google Scholar] [CrossRef] [PubMed]
- Phadke, V.K.; Scanlon, N.; Jordan, S.C.; Rouphael, N.G. Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients. Curr. Transplant. Rep. 2021, 8, 127–139. [Google Scholar] [CrossRef]
- Eckerle, I.; Rosenberger, K.D.; Zwahlen, M.; Junghanss, T. Serologic vaccination response after solid organ transplantation: A systematic review. PLoS ONE 2013, 8, e56974. [Google Scholar] [CrossRef] [Green Version]
- Korth, J.; Jahn, M.; Dorsch, O.; Anastasiou, O.E.; Sorge-Hädicke, B.; Eisenberger, U.; Gäckler, A.; Dittmer, U.; Witzke, O.; Wilde, B.; et al. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech). Viruses 2021, 13, 756. [Google Scholar] [CrossRef]
- Rabinowich, L.; Grupper, A.; Baruch, R.; Ben-Yehoyada, M.; Halperin, T.; Turner, D.; Katchman, E.; Levi, S.; Houri, I.; Lubezky, N.; et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J. Hepatol. 2021, 75, 435–438. [Google Scholar] [CrossRef] [PubMed]
- Rashidi-Alavijeh, J.; Frey, A.; Passenberg, M.; Korth, J.; Zmudzinski, J.; Anastasiou, O.E.; Saner, F.H.; Jahn, M.; Lange, C.M.; Willuweit, K. Humoral Response to SARS-Cov-2 Vaccination in Liver Transplant Recipients-A Single-Center Experience. Vaccines 2021, 9, 738. [Google Scholar] [CrossRef]
- Rusk, D.S.; Strachan, C.C.; Hunter, B.R. Lack of immune response after mRNA vaccination to SARS-CoV-2 in a solid organ transplant patient. J. Med. Virol. 2021, 93, 5623–5625. [Google Scholar] [CrossRef]
- Gobbi, F.; Buonfrate, D.; Moro, L.; Rodari, P.; Piubelli, C.; Caldrer, S.; Riccetti, S.; Sinigaglia, A.; Barzon, L. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection. Viruses 2021, 13, 422. [Google Scholar] [CrossRef]
- Rabets, A.; Bila, G.; Grytsko, R.; Samborskyy, M.; Rebets, Y.; Vari, S.G.; Pagneux, Q.; Barras, A.; Boukherroub, R.; Szunerits, S.; et al. The Potential of Developing Pan-Coronaviral Antibodies to Spike Peptides in Convalescent COVID-19 Patients. Arch. Immunol. Ther. Exp. 2021, 69, 5. [Google Scholar] [CrossRef] [PubMed]
- Barda, N.; Dagan, N.; Cohen, C.; Hernán, M.A.; Lipsitch, M.; Kohane, I.S.; Reis, B.Y.; Balicer, R.D. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study. Lancet 2021, 398, 2093–2100. [Google Scholar] [CrossRef]
- Wise, J. Covid-19: UK will offer third vaccine dose to severely immunosuppressed people. Bmj 2021, 374, n2160. [Google Scholar] [CrossRef]
- Wheeler, S.E.; Shurin, G.V.; Yost, M.; Anderson, A.; Pinto, L.; Wells, A.; Shurin, M.R. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiol. Spectr. 2021, 9, e0034121. [Google Scholar] [CrossRef] [PubMed]
- Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP); National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. Available online: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html (accessed on 23 November 2021).
- Kohmer, N.; Westhaus, S.; Rühl, C.; Ciesek, S.; Rabenau, H.F. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. J. Clin. Virol. 2020, 129, 104480. [Google Scholar] [CrossRef]
- World Health Organisation. Establishment of the WHO International Standard and Reference Panel for Anti-SARS-CoV-2 Antibody. Available online: https://www.who.int/publications/m/item/WHO-BS-2020.2403 (accessed on 23 November 2021).
- Galli, C.; Daghfal, D.; Averhoff, F. Antibody Testing for SARS-CoV-2 Infection, Quantitative Determination, Response to Vaccines and Viral Variability, Abbott Laboratories. Available online: https://www.corelaboratory.abbott/int/en/offerings/segments/infectious-disease/sars-cov-2- (accessed on 2 December 2021).
- Wei, J.; Stoesser, N.; Matthews, P.C.; Ayoubkhani, D.; Studley, R.; Bell, I.; Bell, J.I.; Newton, J.N.; Farrar, J.; Diamond, I.; et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat. Microbiol. 2021, 6, 1140–1149. [Google Scholar] [CrossRef]
- Grupper, A.; Rabinowich, L.; Schwartz, D.; Schwartz, I.F.; Ben-Yehoyada, M.; Shashar, M.; Katchman, E.; Halperin, T.; Turner, D.; Goykhman, Y.; et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am. J. Transplant. 2021, 21, 2719–2726. [Google Scholar] [CrossRef]
- Boyarsky, B.J.; Werbel, W.A.; Avery, R.K.; Tobian, A.A.R.; Massie, A.B.; Segev, D.L.; Garonzik-Wang, J.M. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. JAMA 2021, 325, 1784–1786. [Google Scholar] [CrossRef] [PubMed]
- Cornberg, M.; Eberhardt, C.S. Protected or not protected, that is the question-First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients. J. Hepatol. 2021, 75, 265–266. [Google Scholar] [CrossRef]
- Subesinghe, S.; Bechman, K.; Rutherford, A.I.; Goldblatt, D.; Galloway, J.B. A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. J. Rheumatol. 2018, 45, 733–744. [Google Scholar] [CrossRef] [PubMed]
- Vassilaki, N.; Gargalionis, A.N.; Bletsa, A.; Papamichalopoulos, N.; Kontou, E.; Gkika, M.; Patas, K.; Theodoridis, D.; Manolis, I.; Ioannidis, A.; et al. Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers. Microorganisms 2021, 9, 1725. [Google Scholar] [CrossRef] [PubMed]
- Deepak, P.; Kim, W.; Paley, M.A.; Yang, M.; Carvidi, A.B.; Demissie, E.G.; El-Qunni, A.A.; Haile, A.; Huang, K.; Kinnett, B.; et al. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study. Ann. Intern. Med. 2021, 174, 1572–1585. [Google Scholar] [CrossRef] [PubMed]
- Jalkanen, P.; Kolehmainen, P.; Häkkinen, H.K.; Huttunen, M.; Tähtinen, P.A.; Lundberg, R.; Maljanen, S.; Reinholm, A.; Tauriainen, S.; Pakkanen, S.H.; et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat. Commun. 2021, 12, 3991. [Google Scholar] [CrossRef]
- Krause, P.R.; Fleming, T.R.; Peto, R.; Longini, I.M.; Figueroa, J.P.; Sterne, J.A.C.; Cravioto, A.; Rees, H.; Higgins, J.P.T.; Boutron, I.; et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet 2021, 398, 1377–1380. [Google Scholar] [CrossRef]
- Masset, C.; Kerleau, C.; Garandeau, C.; Ville, S.; Cantarovich, D.; Hourmant, M.; Kervella, D.; Houzet, A.; Guillot-Gueguen, C.; Guihard, I.; et al. A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response. Kidney Int. 2021, 100, 1132–1135. [Google Scholar] [CrossRef]
- Bar-On, Y.M.; Goldberg, Y.; Mandel, M.; Bodenheimer, O.; Freedman, L.; Kalkstein, N.; Mizrahi, B.; Alroy-Preis, S.; Ash, N.; Milo, R.; et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N. Engl. J. Med. 2021, 385, 1393–1400. [Google Scholar] [CrossRef] [PubMed]
- Werbel, W.A.; Boyarsky, B.J.; Ou, M.T.; Massie, A.B.; Tobian, A.A.R.; Garonzik-Wang, J.M.; Segev, D.L. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Ann. Intern. Med. 2021, 174, 1330–1332. [Google Scholar] [CrossRef] [PubMed]
- Del Bello, A.; Abravanel, F.; Marion, O.; Couat, C.; Esposito, L.; Lavayssière, L.; Izopet, J.; Kamar, N. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am. J. Transplant. 2021. [CrossRef] [PubMed]
- Thomas, S.J.; Moreira, E.D., Jr.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Polack, F.P.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N. Engl. J. Med. 2021, 385, 1761–1773. [Google Scholar] [CrossRef]
- Yan, S.; Sun, H.; Bu, X.; Wan, G. New Strategy for COVID-19: An Evolutionary Role for RGD Motif in SARS-CoV-2 and Potential Inhibitors for Virus Infection. Front. Pharmacol. 2020, 11, 912. [Google Scholar] [CrossRef] [PubMed]
- Rivas-Santiago, B.; Jacobo-Delgado, Y.; Rodriguez-Carlos, A. Are Host Defense Peptides and Their Derivatives Ready to be Part of the Treatment of the Next Coronavirus Pandemic? Arch. Immunol. Ther. Exp. 2021, 69, 25. [Google Scholar] [CrossRef]
Figure 1.
Enrollment flow chart and response to vaccination after the second dose of BNT162b2 vaccine. * Other measurement units of anti-SARS-CoV-2 spike protein antibody titer than AU/mL. Anti-S1 Ab = anti-SARS-CoV-2 spike protein antibody; 1st dose = 4–6 weeks after the first dose of vaccination; 2nd dose = 4–8 weeks after the second dose of vaccination.
Figure 1.
Enrollment flow chart and response to vaccination after the second dose of BNT162b2 vaccine. * Other measurement units of anti-SARS-CoV-2 spike protein antibody titer than AU/mL. Anti-S1 Ab = anti-SARS-CoV-2 spike protein antibody; 1st dose = 4–6 weeks after the first dose of vaccination; 2nd dose = 4–8 weeks after the second dose of vaccination.
Figure 2.
Anti-SARS-CoV-2 spike protein Ab production in response to BNT162b2 vaccination in KTRs and LTRs. Immune response to vaccination depending on the type of transplanted organ. Values are presented as the scatter-dot plot with median (middle line), lower (25%), and upper (75%) quartile (as whiskers); the p-value was calculated with the non-parametric Mann–Whitney U Test. (A) All patients including positive history of COVID-19 infection (confirmed by PCR test), (B) patients without confirmed COVID-19 infection. 1st dose = 4–6 weeks after the first dose of vaccination; 2nd dose = 4–8 weeks after the second dose of vaccination; BNT162b2 = BioNTech/Pfizer COVID-19 mRNA vaccine; KTRs = kidney transplant recipients; LTRs = liver transplant recipients; n.s. = not significant.
Figure 2.
Anti-SARS-CoV-2 spike protein Ab production in response to BNT162b2 vaccination in KTRs and LTRs. Immune response to vaccination depending on the type of transplanted organ. Values are presented as the scatter-dot plot with median (middle line), lower (25%), and upper (75%) quartile (as whiskers); the p-value was calculated with the non-parametric Mann–Whitney U Test. (A) All patients including positive history of COVID-19 infection (confirmed by PCR test), (B) patients without confirmed COVID-19 infection. 1st dose = 4–6 weeks after the first dose of vaccination; 2nd dose = 4–8 weeks after the second dose of vaccination; BNT162b2 = BioNTech/Pfizer COVID-19 mRNA vaccine; KTRs = kidney transplant recipients; LTRs = liver transplant recipients; n.s. = not significant.
Figure 3.
Anti-SARS-CoV-2 spike protein Ab production in response to BNT162b2 vaccination in KTRs and LTRs. Immune response to vaccination depending on the type of transplanted organ. Values are presented as the scatter-dot plot with median (middle line), lower (25%), and upper (75%) quartile (as whiskers); the p-value was calculated with the non-parametric Mann–Whitney U Test. (A) All patients including positive history of COVID-19 (confirmed by PCR test), (B) Patients without confirmed COVID-19. Δ anti-S1 Ab—difference in anti-SARS-CoV-2 spike protein antibody concentration between the first and the second dose of the vaccination; BNT162b2 = BioNTech/Pfizer COVID-19 mRNA vaccine; KTRs = kidney transplant recipients; LTRs = liver transplant recipients; n.s. = not significant.
Figure 3.
Anti-SARS-CoV-2 spike protein Ab production in response to BNT162b2 vaccination in KTRs and LTRs. Immune response to vaccination depending on the type of transplanted organ. Values are presented as the scatter-dot plot with median (middle line), lower (25%), and upper (75%) quartile (as whiskers); the p-value was calculated with the non-parametric Mann–Whitney U Test. (A) All patients including positive history of COVID-19 (confirmed by PCR test), (B) Patients without confirmed COVID-19. Δ anti-S1 Ab—difference in anti-SARS-CoV-2 spike protein antibody concentration between the first and the second dose of the vaccination; BNT162b2 = BioNTech/Pfizer COVID-19 mRNA vaccine; KTRs = kidney transplant recipients; LTRs = liver transplant recipients; n.s. = not significant.
Figure 4.
Anti-SARS-CoV-2 spike protein Ab concentration after the second dose in response to BNT162b2 vaccination in LTRs with autoimmune or non-autoimmune etiology of liver transplantation. Post-vaccination antibodies production in LTRs with autoimmune (autoimmune hepatitis, primary biliary cirrhosis or primary sclerosing cholangitis) and non-autoimmune causes of liver transplantation. Values are presented as the scatter-dot plot with median (middle line), lower (25%), and upper (75%) quartile (as whiskers); the p-value was calculated with the non-parametric Mann–Whitney U Test. 2nd dose = 4–8 weeks after the second dose of vaccination; BNT162b2 = BioNTech/Pfizer COVID-19 mRNA vaccine; LTRs = liver transplant recipients; n.s. = not significant.
Figure 4.
Anti-SARS-CoV-2 spike protein Ab concentration after the second dose in response to BNT162b2 vaccination in LTRs with autoimmune or non-autoimmune etiology of liver transplantation. Post-vaccination antibodies production in LTRs with autoimmune (autoimmune hepatitis, primary biliary cirrhosis or primary sclerosing cholangitis) and non-autoimmune causes of liver transplantation. Values are presented as the scatter-dot plot with median (middle line), lower (25%), and upper (75%) quartile (as whiskers); the p-value was calculated with the non-parametric Mann–Whitney U Test. 2nd dose = 4–8 weeks after the second dose of vaccination; BNT162b2 = BioNTech/Pfizer COVID-19 mRNA vaccine; LTRs = liver transplant recipients; n.s. = not significant.
Figure 5.
Immune response to BNT162b2 vaccination depending on the type of transplanted organ and age (A,B) or gender (C,D). Association of the Δanti-S1Ab with age in KTRs (A) and LTRs (B) was calculated with Spearman’s correlation, separate values were fitted with simple linear regression with 95% confidence interval; the scatter-dot plot (C,D) with median (middle line), lower (25%), and upper (75%) quartile (as whiskers), the p-value was calculated with non-parametric Mann–Whitney U Test, Δ anti-S1 Ab—difference in anti-SARS-CoV-2 spike protein antibody concentration between 1st and 2nd dose of the vaccine; 1st dose = 4–6 weeks after the first dose of vaccination; 2nd dose = 4–8 weeks after the second dose of vaccination; BNT162b2 = BioNTech/Pfizer COVID-19 mRNA vaccine; KTRs = kidney transplant recipients; LTRs = liver transplant recipients; n.s. = not significant; R—Spearman’s coefficient.
Figure 5.
Immune response to BNT162b2 vaccination depending on the type of transplanted organ and age (A,B) or gender (C,D). Association of the Δanti-S1Ab with age in KTRs (A) and LTRs (B) was calculated with Spearman’s correlation, separate values were fitted with simple linear regression with 95% confidence interval; the scatter-dot plot (C,D) with median (middle line), lower (25%), and upper (75%) quartile (as whiskers), the p-value was calculated with non-parametric Mann–Whitney U Test, Δ anti-S1 Ab—difference in anti-SARS-CoV-2 spike protein antibody concentration between 1st and 2nd dose of the vaccine; 1st dose = 4–6 weeks after the first dose of vaccination; 2nd dose = 4–8 weeks after the second dose of vaccination; BNT162b2 = BioNTech/Pfizer COVID-19 mRNA vaccine; KTRs = kidney transplant recipients; LTRs = liver transplant recipients; n.s. = not significant; R—Spearman’s coefficient.
Table 1.
Demographic and clinical characteristics of study participants *.
| Characteristics | KTRs (n = 61) | LTRs (n = 55) |
|---|---|---|
| Mean age (SD), years | 54.4 (12.9) | 58.4 (13.3) |
| Median age (Range), years | ||
| Female | 61 (31–77) | 60 (26–82) |
| Male | 53.5 (18–71) | 65 (50–71) |
| Gender, n (%) | ||
| Female | 33 (54.1) | 21 (43.6) |
| Male | 28 (45.9) | 44 (80) |
| Mean BMI (SD), kg/m2 | 25.1 (3.9) | 25.7 (4.0) |
| Mean time since transplantation (SD), years | 13 (7.1) | 14.8 (3.8) |
| History of COVID-19 infection, n (%) | ||
| Infection confirmed by PCR | 5 (8.2) | 5 (9.1) |
| Hospitalization due to COVID-19 | 3 (60) † | 1 (20) † |
| Symptoms: | ||
| Fever >38 °C | 3 (60) | 4 (80) |
| Loss of smell and/or taste | 0 (0) | 3 (60) |
| Dyspnea | 2 (40) | 2 (40) |
| Sore throat | 1 (20) | 1 (20) |
| Myalgia | 2 (40) | 3 (60) |
| Cough | 2 (40) | 2 (40) |
| Pneumoniae | 2 (40) | 2 (40) |
| Tachycardia/arrythmia | 0 | 3 (40) |
| Diarrhea | 1 (20) | 3 (40) |
| Other | 1 (20) | 2 (40) |
| Induction therapy, n (%) | ||
| Anti-thymocyte globulin | 0 | 0 |
| Anti-interleukin-2 receptor | 0 | 30 (54.5) |
| Immunosuppression, n (%) | ||
| Steroids | 52 (85.2) | 20 (36.4) |
| Mycophenolate mofetil | 47 (77.1) | 16 (29.1) |
| Azathioprine | 7 (11.5) | 5 (9.1) |
| Cyclosporine | 25 (41) | 11 (20) |
| Tacrolimus | 33 (54.1) | 43 (78.2) |
| Sirolimus | 2 (3.3) | 2 (3.6) |
| Everolimus | 1 (1.6) | 2 (3.6) |
| Immunosuppression, n (%) | ||
| Mono-therapy (CNI/MMF) | 0 | 24 (43.6) |
| Dual-therapy (CNI + GKS/MMF/AZA/mTORI) | 16 (26.3) | 18 (32.7) |
| Triple-therapy (CNI/mTORi +GKS + MMF/AZA) | 45 (73.8) | 13 (23.6) |
| Mean laboratory data (SD) | ||
| Serum creatinine, mg/dL | 1.4 (0.5) | 1 (0.3) |
| eGFR, mL/min * 1.73 m2 | 51.3 (16.8) | 58.4 (19.1) |
| ALT, IU/L | 18.6 (10.5) | 25.1 (17.7) |
| AST, IU/L | n.a. | 26.4 (15.4) |
| GGTP, IU/L | n.a. | 70 (78.3) |
| ALP, IU/L | n.a. | 109.4 (65.4) |
| Bil, mg/dL | n.a. | 1.3 (2.4) |
| Complement component | ||
| C3 G/L | 1.2 (0.3) | 1.3 (0.3) |
| C4 G/L | 0.2 (0.1) | 0.2 (0.1) |
* Parameters determined after 4–8 weeks after the second dose of BNT162b2 vaccination. † Percent of infection confirmed by PCR. ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; AZA = azathioprine; Bil = bilirubin; BMI = body mass index; BNT162b2 = BioNTech/Pfizer COVID-19 mRNA vaccine; CNI = calcineurin inhibitor including cyclosporine and tacrolimus; Cr = creatinine; GFR = glomerular filtration rate (estimated with CKD-EPI formula); GGTP = gamma-glutamyltranspeptidase; GKS = corticosteroids; KTRs = kidney transplant recipients; LTRs = liver transplant recipients; MMF = mycophenolate mofetil; mTORi = mTOR kinase inhibitors including everolimus and sirolimus; n.a. = not available.
Table 2.
Comparison of SARS-CoV-2 spike protein Ab concentration (AU/mL) after BNT162b2 vaccination in KTRs and LTRs.
Table 2.
Comparison of SARS-CoV-2 spike protein Ab concentration (AU/mL) after BNT162b2 vaccination in KTRs and LTRs.
| Parameter | KTRs + LTRs (n) | MD (IQR) | KTRs (n) | MD (IQR) | LTRs (n) | MD (IQR) | p-Value * |
|---|---|---|---|---|---|---|---|
| All patients: positive history of COVID-19 disease (confirmed by PCR test) included | |||||||
| Δ anti-S1 Ab † | 76 | 725.4 (4434.4) | 40 | 604 (4635.6) | 36 | 730.1 (4384) | 0.84 |
| Ab after the 2nd dose | 94 | 2238.2 (10,475.2) | 49 | 860 (9198.9) | 45 | 4351 (15,024.7) | 0.032 |
| Ab after the 1st dose | 98 | 73.2 (5639.9) | 52 | 39.1 (4549) | 46 | 231.7 (6192) | 0.197 |
| Patients without a positive history of COVID-19 disease | |||||||
| Δ anti-S1 Ab † | 69 | 402.1 (4178) | 36 | 55.4 (4512.1) | 33 | 869.4 (4037) | 0.477 |
| Ab after the 2nd dose | 87 | 1210.2 (8910.5) | 45 | 99.5 (5077.6) | 42 | 3193.55 (10,112) | 0.017 |
| Ab after the 1st dose | 88 | 48.8 (1788.8) | 47 | 23.8 (1945.3) | 41 | 148 (1263.3) | 0.266 |
n—number of observations; values are set as median (MD) and interquartile range (IQR); * Mann–Whitney test; p < 0.05 was considered statistically significant (comparison of variables in a group of KTRs and LTRs); † difference between anti-SARS-CoV-2 spike protein antibody titer after the first and second doses of BNT162b2 vaccine; 1st dose = 4–6 weeks after the first dose of vaccination; 2nd dose = 4–8 weeks after the second dose of vaccination; Ab = SARS-CoV-2 spike protein antibody; BNT162b2 = BioNTech/Pfizer COVID-19 mRNA vaccine; KTRs = kidney transplant recipients; LTRs = liver transplant recipients.
Table 3.
Correlations of SARS-CoV-2 spike protein Ab concentration (AU/mL) after BNT162b2 vaccination with clinical variables.
Table 3.
Correlations of SARS-CoV-2 spike protein Ab concentration (AU/mL) after BNT162b2 vaccination with clinical variables.
| Parameter | All Patients | KTRs | LTRs | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n | p-Value * | R | n | p-Value * | R | n | p-Value * | R | |
| Correlations with Δ anti-S1 Ab † | |||||||||
| Anti-N Ab ‡, S/CO | 75 | 0.103 | 0.190 | 40 | 0.43 | 0.006 | 35 | 0.64 | −0.082 |
| Age, years | 76 | 0.005 | −0.317 | 40 | 0.004 | −0.447 | 36 | 0.31 | −0.174 |
| BMI, kg/m2 | 76 | 0.071 | −0.208 | 40 | 0.29 | −0.170 | 36 | 0.148 | −0.246 |
| Time from transplantation, years | 76 | 0.87 | 0.020 | 40 | 0.99 | 0.002 | 36 | 0.80 | −0.043 |
| CSA | |||||||||
| daily dose, mg | 21 | 0.70 | 0.089 | 13 | 0.74 | 0.100 | 8 | 0.47 | 0.299 |
| Concentration ‡, ng/mL | 21 | 0.48 | −0.163 | 13 | 0.61 | −0.156 | 8 | 0.74 | −0.143 |
| TAC | |||||||||
| daily dose, mg | 53 | 0.22 | 0.171 | 25 | 0.50 | 0.142 | 28 | 0.37 | 0.200 |
| Concentration ‡, ng/mL | 52 | 0.30 | −0.148 | 24 | 0.46 | −0.158 | 28 | 0.23 | −0.233 |
| Graft function | |||||||||
| Cr, mg/dL | 65 | 0.26 | −0.141 | 37 | 0.59 | −0.090 | 28 | 0.145 | −0.282 |
| GFR, mL/min × 1.73 m2 | 66 | 0.036 | 0.259 | 37 | 0.102 | 0.273 | 29 | 0.35 | 0.179 |
| AST, IU/L | 67 | 0.41 | 0.102 | 34 | 0.82 | 0.039 | 33 | 0.124 | 0.273 |
| ALT, IU/L | 37 | 0.56 | 0.100 | 5 | 0.39 | −0.500 | 32 | 0.32 | 0.183 |
| ALP, IU/L | 35 | 0.41 | 0.144 | 4 | 0.37 | −0.632 | 31 | 0.31 | 0.189 |
| Bil, mg/dL | 35 | 0.51 | −0.115 | 3 | n.a. | n.a. | 32 | 0.79 | −0.050 |
| GGTP, IU/L | 30 | 0.115 | −0.294 | 1 | n.a. | n.a. | 29 | 0.188 | −0.252 |
| Complement component, G/L | |||||||||
| C3 | 56 | 0.54 | −0.084 | 30 | 0.96 | 0.010 | 26 | 0.25 | −0.235 |
| C4 | 55 | 0.26 | −0.155 | 30 | 0.52 | −0.123 | 25 | 0.43 | −0.166 |
| Correlations with anti-S1 Ab after the 2nd dose | |||||||||
| Anti-N Ab §, S/CO | 35 | 0.040 | 0.409 | 25 | 0.106 | 0.331 | 20 | 0.41 | 0.194 |
| Age, years | 94 | 0.014 | −0.253 | 49 | <0.001 | −0.467 | 45 | 0.62 | −0.076 |
| BMI, kg/m2 | 94 | 0.74 | 0.034 | 49 | 0.77 | 0.042 | 45 | 0.96 | 0.008 |
| Time from transplantation, years | 94 | 0.32 | 0.104 | 49 | 0.25 | 0.169 | 45 | 0.25 | −0.174 |
| CSA | |||||||||
| daily dose, mg | 30 | 0.27 | 0.209 | 20 | 0.062 | 0.425 | 10 | 0.45 | 0.271 |
| Concentration §, ng/mL | 28 | 0.81 | 0.049 | 20 | 0.63 | 0.114 | 8 | 0.46 | 0.310 |
| TAC | |||||||||
| daily dose, mg | 62 | 0.119 | 0.200 | 27 | 0.69 | 0.080 | 35 | 0.040 | 0.349 |
| Concentration §, ng/mL | 57 | 0.180 | −0.180 | 26 | 0.87 | 0.033 | 31 | 0.162 | −0.257 |
| Correlations with anti-S1 Ab after the 1st dose | |||||||||
| Anti-N Ab ‡, S/CO | 97 | <0.001 | 0.671 | 52 | <0.001 | 0.632 | 45 | <0.001 | 0.711 |
| Age, years | 97 | <0.001 | −0.346 | 52 | <0.001 | −0.462 | 45 | 0.139 | −0.224 |
| BMI, kg/m2 | 94 | 0.86 | 0.018 | 50 | 0.51 | 0.096 | 44 | 0.86 | −0.027 |
| Time from transplantation, years | 94 | 0.181 | 0.139 | 49 | 0.23 | 0.173 | 45 | 0.96 | −0.007 |
| CSA | |||||||||
| daily dose, mg | 27 | 0.188 | 0.261 | 18 | 0.33 | 0.245 | 9 | 0.24 | 0.434 |
| Concentration ‡, ng/mL | 27 | 0.088 | 0.335 | 18 | 0.28 | 0.270 | 9 | 0.081 | 0.610 |
| TAC | |||||||||
| daily dose, mg | 67 | 0.057 | 0.234 | 31 | 0.163 | 0.257 | 36 | 0.26 | 0.194 |
| Concentration ‡, ng/mL | 65 | 0.56 | −0.074 | 29 | 0.68 | −0.080 | 36 | 0.38 | −0.152 |
n—number of observations for selected pairs of parameters. * Spearman’s test; p < 0.05 was considered statistically significant (comparison of variables in a group all participants, KTRs and LTRs). † Difference between anti-SARS-CoV-2 spike protein antibody titer after the first and second doses of BNT162b2 vaccination; ‡ concentration 4–6 weeks after the first dose of vaccination; § concentration 4–8 weeks after the second dose of vaccination; 1st dose = 4–6 weeks after the first dose of vaccination; 2nd dose = 4–8 weeks after the second dose of vaccination; ALP = alkaline phosphatase; ALT = alanine aminotransferase; anti-N Ab = anti-SARS-CoV-2 nucleocapsid protein antibody associated with a reaction to previous contact with the SARS Cov-2 virus; anti-S1 Ab = SARS-Cov-2 spike protein antibody; AST = aspartate aminotransferase; BMI = body mass index; BNT162b2 = BioNTech/Pfizer COVID-19 mRNA vaccine; Cr = creatinine; CSA = Cyclosporine; GFR = glomerular filtration rate (estimated with CKD-EPI formula); GGTP = gamma-glutamyltranspeptidase; KTRs = kidney transplant recipients; LTRs = liver transplant recipients; n.a. = not available; R–spearman’s coefficient; TAC = tacrolimus.
Table 4.
Comparison of SARS-CoV-2 spike protein Ab concentration (AU/mL) after BNT162b2 vaccination with clinical variables.
Table 4.
Comparison of SARS-CoV-2 spike protein Ab concentration (AU/mL) after BNT162b2 vaccination with clinical variables.
| Parameter | All Patients | KTRs | LTRs | ||||
|---|---|---|---|---|---|---|---|
| n | MD (IQR) | n | MD (IQR) | n | MD (IQR) | p-Value * | |
| Comparison to Δ anti-S1 Ab † | |||||||
| Gender | |||||||
| M | 30 | 2509 (7408.8) | 21 | 3398.7 (9104.1) | 9 | 1006.7 (3826.6) | 0.86 |
| F | 46 | 251.5 (3476.8) | 19 | 10.4 (2931.4) | 27 | 590.7 (4612.2) | 0.35 |
| Blood type | |||||||
| A | 29 | 402.1 (4177.5) | 16 | 55 (3164.8) | 13 | 869.4 (7567.6) | 0.32 |
| B | 13 | 351.4 (2974.3) | 5 | 1333.3 (2974.3) | 8 | 291.7 (2769.9) | 0.88 |
| AB | 8 | 1485.7 (6572.6) | 6 | 3060.5 (8275.5) | 2 | −389.6 (779.1) | 0.094 |
| O | 24 | 1147.2 (4813.4) | 11 | 0 (6878.2) | 13 | 1236.7 (3348.5) | 0.64 |
| Comparison to Ab after the 2nd dose | |||||||
| Gender | |||||||
| M | 37 | 2583.7 (9723.5) | 25 | 4587.3 (19,037.8) | 12 | 1128.5 (3824) | 0.26 |
| F | 57 | 1511.5 (10,487.1) | 24 | 12.1 (2996.3) | 33 | 7928 (24,050.8) | <0.001 |
| Comparison to Ab after the 1st dose | |||||||
| Gender | |||||||
| M | 36 | 107.9 (7375.3) | 24 | 119.7 (9196.1) | 12 | 81.2 (304.5) | 0.45 |
| F | 62 | 68.3 (3753.2) | 28 | 2.7 (1560.5) | 34 | 390.7 (10,404.8) | 0.023 |
n = number of observations; values are set as median (MD) and interquartile range (IQR); * Mann–Whitney test; p < 0.05 was considered statistically significant (comparison of KTRs and LTRs); † difference between anti-SARS-CoV-2 spike protein antibody titer after the first and second doses of BNT162b2 vaccine; 1st dose = 4–6 weeks after the first dose of vaccination; 2nd dose = 4–8 weeks after the second dose of vaccination; Ab = SARS-CoV-2 spike protein antibody; BNT162b2 = BioNTech/Pfizer COVID-19 mRNA vaccine; KTRs = kidney transplant recipients; LTRs = liver transplant recipients; F = female, M = male.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Nazaruk, P.; Monticolo, M.; Jędrzejczak, A.M.; Krata, N.; Moszczuk, B.; Sańko-Resmer, J.; Pilecki, T.; Urbanowicz, A.; Florczak, M.; Pączek, L.; et al. Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients—Is It Related to Immunosuppression Only? Vaccines 2021, 9, 1454. https://doi.org/10.3390/vaccines9121454
AMA Style
Nazaruk P, Monticolo M, Jędrzejczak AM, Krata N, Moszczuk B, Sańko-Resmer J, Pilecki T, Urbanowicz A, Florczak M, Pączek L, et al. Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients—Is It Related to Immunosuppression Only? Vaccines. 2021; 9(12):1454. https://doi.org/10.3390/vaccines9121454
Chicago/Turabian StyleNazaruk, Paulina, Marta Monticolo, Anna Maria Jędrzejczak, Natalia Krata, Barbara Moszczuk, Joanna Sańko-Resmer, Tomasz Pilecki, Arkadiusz Urbanowicz, Michał Florczak, Leszek Pączek, and et al. 2021. "Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients—Is It Related to Immunosuppression Only?" Vaccines 9, no. 12: 1454. https://doi.org/10.3390/vaccines9121454
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
